Daptomycin literature

On this page, you can find all the papers I have collected on the daptomycin project. I will update this from time to time. If something important is missing, please let me know.

In order to access the linked PDF files, you have to enter a valid UW user ID. This ID is only shared with the central UW authentication server, not with this page, and is securely transmitted.

Action Mechanism, Membrane Potential

  1. Alborn, W. E. Jr et al. (1991) Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 35:2282-7 PDF

    This is one of two seminal papers on the effect of daptomycin on the membrane potential of bacterial cells.

  2. Allen, N. E. et al. (1991) Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 35:2639-42 PDF

    This is one of two seminal papers on the effect of daptomycin on the membrane potential of bacterial cells.

  3. Allen, N. E. et al. (1987) Inhibition of peptidoglycan biosynthesis in Gram-positive bacteria by LY146032. Antimicrob Agents Chemother 31:1093-9 PDF
  4. Boaretti, M. and Canepari, P. (2000) Purification of daptomycin binding proteins (DBPs) from the membrane of Enterococcus hirae. New Microbiol 23:305-17 PDF
  5. Boaretti, M. and Canepari, P. (1995) Identification of daptomycin-binding proteins in the membrane of Enterococcus hirae. Antimicrob Agents Chemother 39:2068-72 PDF
  6. Boaretti, M. et al. (1993) The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J Antimicrob Chemother 31:227-35 PDF
  7. Canepari, P. et al. (1990) Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 34:1220-6 PDF
  8. Chen, Yen-Fei et al. (2014) Interaction of daptomycin with lipid bilayers: a lipid extracting effect. Biochemistry 53:5384-92 PDF
  9. Cotroneo, Nicole et al. (2008) Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus. Antimicrob Agents Chemother 52:2223-2225 PDF

    This paper demonstrates the absence of membrane disruption visible by electron microscopy.

  10. Eliopoulos, G. M. et al. (1985) In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother 27:357-62 PDF

    A21978C1 is daptomycin, for practical purposes. This paper posits that daptomycin inhibits peptidoglycan synthesis.

  11. Hobbs, Joanne Karen et al. (2008) Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62:1003-8 PDF
  12. Jung, David et al. (2008) Lipid-specific binding of the calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of model membranes. Chem Phys Lipids 154:120-128 PDF
  13. Lakey, J. H. and Lea, E. J. (1986) The role of acyl chain character and other determinants on the bilayer activity of A21978C, an acidic lipopeptide antibiotic. Biochim Biophys Acta 859:219-26 PDF
  14. Lakey, J. H. et al. (1989) The lipopeptide antibiotic A21978C has a specific interaction with DMPC only in the presence of calcium ions. Biochim Biophys Acta 985:60-6 PDF
  15. Lakey, J. H. and Ptak, M. (1988) Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry 27:4639-4645 PDF
  16. Mascio, Carmela T. M. et al. (2007) Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51:4255-4260 PDF
  17. Mengin-Lecreulx, D. et al. (1990) Inhibition of peptidoglycan biosynthesis in Bacillus megaterium by daptomycin. FEMS Microbiol Lett 57:245-8 PDF
  18. something else: thesis (Muraih2012t)


  19. Muraih, Jawad K. and Palmer, Michael (2012) Estimation of the subunit stoichiometry of the membrane-associated daptomycin oligomer by FRET. Biochim Biophys Acta 1818:1642-1647 PDF
  20. Muraih, Jawad K. et al. (2011) Oligomerization of daptomycin on membranes. Biochim Biophys Acta 1808:1154-60 PDF
  21. Muthaiyan, Arunachalam et al. (2008) Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother 52:980-90
  22. Nannini, Esteban et al. (2010) Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 10:516-21
  23. Pogliano, Joe et al. (2012) Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 194:4494-504 PDF
  24. Randall, Christopher P. et al. (2013) The target of daptomycin is absent from Escherichia coli and other gram-negative pathogens. Antimicrob Agents Chemother 57:637-9 PDF
  25. Silverman, Jared A. et al. (2003) Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47:2538-2544 PDF
  26. Taylor, R. M. et al. (2016) Two successive calcium-dependent transitions mediate membrane binding and oligomerization of daptomycin and the related antibiotic A54145. BBA Biomembranes in press:x-x
  27. Taylor, S. D. and Palmer, M. (2016) The action mechanism of daptomycin. Bioorganic and Medicinal Chemistry submitted:x-x
  28. Wale, L. J. et al. (1989) Scanning electronmicroscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin. J Med Microbiol 30:45-9 PDF
  29. Zhang, T. et al. (2014) Daptomycin forms cation- and size-selective pores in model membranes. Biochim Biophys Acta 1838:2425-2430 PDF
  30. Zhang, T. et al. (2016) Membrane binding and oligomer formation of the calcium-dependent lipopeptide antibiotic A54145: a quantitative study with pyrene excimer fluorescence. Biophys J (submitted):x-x
  31. Zhang, Tianhua et al. (2013) Mutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462. Biochim Biophys Acta 1828:302-8 PDF

Analogs / Chemical Synthesis

  1. 't Hart, Peter et al. (2014) A combined solid- and solution-phase approach provides convenient access to analogues of the calcium-dependent lipopeptide antibiotics. Org Biomol Chem 12:913-8
  2. Alexander, Dylan C. et al. (2011) Production of novel lipopeptide antibiotics related to A54145 by Streptomyces fradiae mutants blocked in biosynthesis of modified amino acids and assignment of lptJ, lptK and lptL gene functions. J Antibiot (Tokyo) 64:79-87 PDF
  3. something else: inproceedings (Counter1980)
  4. Dartois, Véronique et al. (2005) Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother 49:3302-10
  5. Debono, M. et al. (1988) Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J Antibiot (Tokyo) 41:1093-1105 PDF
  6. something else: inproceedings (Debono1980)
  7. Fukuda, D. S. et al. (1990) A54145, a new lipopeptide antibiotic complex: microbial and chemical modification. J Antibiot (Tokyo) 43:601-6 PDF
  8. Grünewald, Jan et al. (2004) Synthesis and derivatization of daptomycin: a chemoenzymatic route to acidic lipopeptide antibiotics. J Am Chem Soc 126:17025-31 PDF
  9. He, Yong et al. (2012) Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids. Bioorg Med Chem Lett 22:6248-51 PDF
  10. Hill, Jason et al. (2003) Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin. Bioorg Med Chem Lett 13:4187-91 PDF
  11. Kopp, Florian et al. (2006) Chemoenzymatic design of acidic lipopeptide hybrids: new insights into the structure-activity relationship of daptomycin and A54145. Biochemistry 45:10474-81 PDF
  12. Lam, Hiu Yung et al. (2013) Total synthesis of daptomycin by cyclization via a chemoselective serine ligation. J Am Chem Soc 135:6272-9
  13. Lohani, C. et al. (2015) Solid-Phase Total Synthesis of Daptomycin and Analogs. Organic Letters 17:748-751 PDF
  14. Lohani, Chuda Raj et al. (2016) α-Azido Acids in Solid-Phase Peptide Synthesis: Compatibility with Fmoc Chemistry and an Alternative Approach to the Solid Phase Synthesis of Daptomycin Analogs. J Org Chem 81:2624-8
  15. Lohani, Chuda Raj et al. (2015) Solid-phase synthesis and in vitro biological activity of a Thr4→Ser4 analog of daptomycin. Bioorg Med Chem Lett 25:5490-4 PDF
  16. Mascio, Carmela T. M. et al. (2014) Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 58:3976-82 PDF
  17. Mascio, Carmela T. M. et al. (2012) In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 56:5023-30 PDF
  18. Mascio, Carmela et al. (2009) Microbiological Characterization of a Novel Lipopeptide Antibiotic with Activity in Pulmonary Surfactant . 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12–15, 2009, San Francisco, CA, American Society For Microbiology, Washington, DC. PDF

    This conference presentation shows the structure of CB-182,462 and compares its activity to daptomycin.

  19. Ng, Julio et al. (2009) Dereplication and de novo sequencing of nonribosomal peptides. Nat Methods 6:596-9
  20. Nguyen, Kien T. et al. (2010) Genetically Engineered Lipopeptide Antibiotics Related to A54145 and Daptomycin with Improved Properties. Antimicrob Agents Chemother 54:1404-1413 PDF
  21. Siedlecki, James et al. (2003) Array synthesis of novel lipodepsipeptide. Bioorg Med Chem Lett 13:4245-4249 PDF
  22. Xiao, Qing and Pei, Dehua (2007) High-throughput synthesis and screening of cyclic peptide antibiotics. J Med Chem 50:3132-7

Biosynthesis, Natural Analogs

  1. Baltz, Richard H. (2008) Biosynthesis and genetic engineering of lipopeptide antibiotics related to daptomycin. Curr Top Med Chem 8:618-38
  2. Baltz, Richard H. (2014) Combinatorial biosynthesis of cyclic lipopeptide antibiotics: a model for synthetic biology to accelerate the evolution of secondary metabolite biosynthetic pathways. ACS Synth Biol 3:748-58 PDF
  3. Baltz, Richard H. et al. (2005) Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep 22:717-41 PDF
  4. Boeck, L. D. et al. (1990) A54145, a new lipopeptide antibiotic complex: discovery, taxonomy, fermentation and HPLC. J Antibiot (Tokyo) 43:587-593
  5. Debono, M. et al. (1987) A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation. J Antibiot (Tokyo) 40:761-77 PDF
  6. Huber, FM et al. (1988) The formation of daptomycin by supplying decanoic acid to Streptomyces roseosporus cultures producing the antibiotic complex A21978C. Journal of Biotechnology 7:283-292 PDF
  7. Liao, Guojian et al. (2013) Manipulation of kynurenine pathway for enhanced daptomycin production in Streptomyces roseosporus. Biotechnol Prog 29:847-852 PDF
  8. Miao, Vivian et al. (2005) Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 151:1507-23 PDF
  9. Sundlov, Jesse A. et al. (2012) Structural and functional investigation of the intermolecular interaction between NRPS adenylation and carrier protein domains. Chem Biol 19:188-98 PDF

Clinical Studies

  1. Benvenuto, Mark et al. (2006) Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50:3245-9 PDF
  2. Cantón, Rafael et al. (2010) A potential role for daptomycin in enterococcal infections: what is the evidence?. J Antimicrob Chemother 65:1126-36
  3. Crompton, Jason A. et al. (2010) Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. J Antimicrob Chemother 65:1784-91
  4. Dvorchik, Barry H. et al. (2003) Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47:1318-23 PDF
  5. Gallagher, Jason C. et al. (2009) Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 29:792-9
  6. Hsu, Li-Yang et al. (2010) Six cases of daptomycin non-susceptible Staphylococcus aureus bacteremia in Singapore. J Med Microbiol -:x-x
  7. Mave, Vidya et al. (2009) Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?. J Antimicrob Chemother 64:175-80
  8. Miller, Becky A. et al. (2010) Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis 50:e63-8
  9. Munita, Jose M. et al. (2014) Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. Int J Antimicrob Agents 44:387-95 PDF
  10. Oleson, F. B. Jr et al. (2000) Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44:2948-53
  11. Popov, Aron F. et al. (2010) Daptomycin as a possible new treatment option for surgical management of Methicillin-Resistant Staphylococcus aureus sternal wound infection after cardiac surgery. J Cardiothorac Surg 5:57
  12. Sakoulas, G. (2009) Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clin Microbiol Infect 15 Suppl 6:11-6
  13. Woodworth, J. R. et al. (1992) Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36:318-25 PDF

General Subjects, Reviews

  1. Baltz, Richard H. (2009) Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 13:144-151 PDF

    A very good introductory review, even if not current with the very latest discoveries.

  2. Eisenstein, Barry I. et al. (2010) Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 50 Suppl 1:S10-5
  3. Glover, K. J. et al. (2001) Structural evaluation of phospholipid bicelles for solution-state studies of membrane-associated biomolecules. Biophys J 81:2163-71
  4. King, V. et al. (2000) Pegylation of magnetically oriented lipid bilayers. J Magn Reson 142:177-82
  5. Kirkpatrick, Peter et al. (2003) Daptomycin. Nat Rev Drug Discov 2:943-4
  6. Kol, M. A. et al. (2001) Membrane-spanning peptides induce phospholipid flop: a model for phospholipid translocation across the inner membrane of E. coli. Biochemistry 40:10500-6
  7. Konings, W. N. et al. (1973) New procedure for the isolation of membrane vesicles of Bacillus subtilis and an electron microscopy study of their ultrastructure. J Bacteriol 116:1456-65 PDF
  8. Leckband, D. E. et al. (1993) Role of calcium in the adhesion and fusion of bilayers. Biochemistry 32:1127-40 PDF
  9. Lohner, Karl (2009) New strategies for novel antibiotics: peptides targeting bacterial cell membranes. Gen Physiol Biophys 28:105-16
  10. Martens-Lobenhoffer, Jens et al. (2008) Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 875:546-550
  11. Mayer, L. D. et al. (1986) Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 858:161-168 PDF
  12. Novo, D. J. et al. (2000) Multiparameter flow cytometric analysis of antibiotic effects on membrane potential, membrane permeability, and bacterial counts of Staphylococcus aureus and Micrococcus luteus. Antimicrob Agents Chemother 44:827-34 PDF
  13. Novo, D. et al. (1999) Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. Cytometry 35:55-63 PDF
  14. Papahadjopoulos, D. and Poste, G. (1975) Calcium-induced phase separation and fusion in phospholipid membranes. Biophys J 15:945-8 PDF
  15. Robbel, Lars and Marahiel, Mohamed A. (2010) Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J Biol Chem 285:27501-8 PDF
  16. Seelig, J. (1990) Interaction of phospholipids with Ca2+ ions. On the role of the phospholipid head groups. Cell Biol Int Rep 14:353-360
  17. Steenbergen, Judith N. et al. (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283-288 PDF
  18. Straus, Suzana K. and Hancock, Robert E. W. (2006) Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 1758:1215-1223 PDF
  19. Strieker, Matthias and Marahiel, Mohamed A. (2009) The structural diversity of acidic lipopeptide antibiotics. Chembiochem 10:607-16 PDF

    A good overview of daptomycin and the related amphomycin family of lipopeptides.

  20. Tally, F. P. and DeBruin, M. F. (2000) Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 46:523-526 PDF
  21. Tobin, C. M. et al. (2008) An HPLC assay for daptomycin in serum. J Antimicrob Chemother 62:1462-1463
  22. Tsentalovich, Yuri P. et al. (2005) Photochemistry of kynurenine, a tryptophan metabolite: properties of the triplet state. J Phys Chem A 109:3565-8 PDF
  23. Walsh, Christopher T. and Fischbach, Michael A. (2010) Natural products version 2.0: connecting genes to molecules. J Am Chem Soc 132:2469-93 PDF
  24. something else: thesis (Zhang2014c)


  1. Andrew, J. H. et al. (1987) The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J Antimicrob Chemother 20:213-21 PDF
  2. Andrä, Jörg et al. (2011) Multiple peptide resistance factor (MprF)-mediated Resistance of Staphylococcus aureus against antimicrobial peptides coincides with a modulated peptide interaction with artificial membranes comprising lysyl-phosphatidylglycerol. J Biol Chem 286:18692-700
  3. Appleman, Maria D. and Citron, Diane M. (2010) Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years. Diagn Microbiol Infect Dis 66:441-4
  4. Arias, Cesar A. et al. (2011) Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365:892-900 PDF
  5. Bell, Jan M. et al. (2010) Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008). Pathology 42:470-3
  6. Bertsche, Ute et al. (2011) Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob Agents Chemother 55:3922-8 PDF
  7. Bertsche, Ute et al. (2013) Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. PLoS One 8:e67398
  8. Cameron, David R. et al. (2015) Impact of daptomycin resistance on Staphylococcus aureus virulence. Virulence 6:127-31
  9. D'Costa, Vanessa M. et al. (2012) Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms. Antimicrob Agents Chemother 56:757-64 PDF
  10. Davlieva, Milya et al. (2015) A variable DNA recognition site organization establishes the LiaR-mediated cell envelope stress response of enterococci to daptomycin. Nucleic Acids Res 43:4758-73 PDF
  11. Davlieva, Milya et al. (2013) Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci. Antimicrob Agents Chemother 57:289-96 PDF
  12. Diaz, Lorena et al. (2014) Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs. Antimicrob Agents Chemother 58:4527-34
  13. Eliopoulos, G. M. et al. (1986) In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother 30:532-5 PDF
  14. Ernst, Christoph M. and Peschel, Andreas (2011) Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol Microbiol 80:290-9
  15. Ernst, Christoph M. et al. (2009) The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 5:e1000660
  16. Fischer, Adrien et al. (2011) Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother 66:1696-711
  17. Friedman, Lisa et al. (2006) Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50:2137-45 PDF
  18. Hachmann, Anna-Barbara et al. (2009) Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin. Antimicrob Agents Chemother 53:1598-609 PDF
  19. Hachmann, Anna-Barbara et al. (2011) Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Antimicrob Agents Chemother 55:4326-4337 PDF
  20. Humphries, Romney M. et al. (2012) Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 56:6051-3 PDF
  21. Kelesidis, Theodoros et al. (2012) De novo daptomycin-nonsusceptible enterococcal infections. Emerg Infect Dis 18:674-6 PDF
  22. Kilelee, Erin et al. (2010) Lysyl-Phosphatidylglycerol Attenuates Membrane Perturbation Rather than Surface Association of the Cationic Antimicrobial Peptide 6W-RP-1 in a Model Membrane System: Implications for Daptomycin Resistance. Antimicrob Agents Chemother -:x-x PDF
  23. Kosmidis, Christos and Levine, Donald P. (2010) Daptomycin: pharmacology and clinical use. Expert Opin Pharmacother 11:615-25 PDF
  24. Laganas, Valerie et al. (2003) In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother 47:2682-2684 PDF
  25. Livermore, David M. (2008) Future directions with daptomycin. J Antimicrob Chemother 62 Suppl 3:iii41-iii49 PDF
  26. Lohner, K. and Blondelle, S. E. (2005) Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb Chem High Throughput Screen 8:241-56
  27. Mangoni, Maria Luisa and Shai, Yechiel (2011) Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action. Cell Mol Life Sci 68:2267-80 PDF
  28. Miller, Corwin et al. (2013) Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance. Antimicrob Agents Chemother 57:5373-83
  29. Mishra, Nagendra N. and Bayer, Arnold S. (2013) Correlation of Cell Membrane Lipid Profiles with Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:1082-5 PDF
  30. Mishra, Nagendra N. et al. (2012) Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLoS One 7:e43958 PDF
  31. Mishra, Nagendra N. et al. (2011) In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:4012-8
  32. Mishra, Nagendra N. et al. (2013) Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One 8:e71151
  33. Moise, Pamela A. et al. (2009) Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 9:617-24
  34. Morris, C. M. et al. (1995) Effect of polymyxin B nonapeptide on daptomycin permeability and cell surface properties in Pseudomonas aeruginosa, Escherichia coli, and Pasteurella multocida. J Antibiot (Tokyo) 48:67-72
  35. Munita, Jose M. et al. (2014) Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Clin Infect Dis 59:1277-80
  36. Nannini, Esteban et al. (2010) Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 10:516-21
  37. Nishi, Hiromi et al. (2004) Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, in Staphylococcus aureus. Antimicrob Agents Chemother 48:4800-7
  38. Palmer, Kelli L. et al. (2011) Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 55:3345-56 PDF
  39. Panesso, Diana et al. (2015) Deletion of liaR Reverses Daptomycin Resistance in Enterococcus faecium Independent of the Genetic Background. Antimicrob Agents Chemother 59:7327-34 PDF
  40. Peleg, Anton Y. et al. (2012) Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 7:e28316 PDF
  41. Pillai, Satish K. et al. (2007) Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 51:2223-5
  42. Reyes, Jinnethe et al. (2015) A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis. J Infect Dis 211:1317-25 PDF
  43. Rubinchik, E. et al. (2011) Mechanism of action and limited cross-resistance of new lipopeptide MX-2401. Antimicrob Agents Chemother 55:2743-54 PDF
  44. Rubio, Aileen et al. (2011) Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus. Antimicrob Agents Chemother 55:364-7
  45. Rubio, Aileen et al. (2012) LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and -resistant isolates of Staphylococcus aureus with mutations in mprF. Mol Membr Biol 29:1-8
  46. Sakoulas, George et al. (2012) Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 56:838-44
  47. Sakoulas, George et al. (2014) Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 58:1494-500
  48. Smith, Shannon M. et al. (2008) An enhanced miniaturized assay for antimicrobial prospecting. J Microbiol Methods 72:103-6 PDF
  49. Staubitz, Petra et al. (2004) MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol Lett 231:67-71
  50. Stefani, Stefania et al. (2015) Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence. Int J Antimicrob Agents 46:278-89 PDF
  51. Tally, F. P. et al. (1999) Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs 8:1223-1238 PDF
  52. Tran, Truc T. et al. (2015) Mechanisms of drug resistance: daptomycin resistance. Ann N Y Acad Sci 1354:32-53
  53. Tran, Truc T. et al. (2013) Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 57:261-8 PDF
  54. Tran, Truc T. et al. (2013) Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio 4:x-x PDF
  55. Wecke, Tina et al. (2009) Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses. Antimicrob Agents Chemother 53:1619-23 PDF
  56. Wolf, Diana et al. (2012) Cell Envelope Stress Response in Cell Wall-Deficient L-Forms of Bacillus subtilis. Antimicrob Agents Chemother 56:5907-15 PDF
  57. Wolf, Diana et al. (2010) In-depth profiling of the LiaR response of Bacillus subtilis. J Bacteriol 192:4680-93 PDF
  58. Yang, Soo-Jin et al. (2009) Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200:1916-20 PDF
  59. Yang, Soo-Jin et al. (2013) Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother 57:5658-64
  60. Yang, Soo-Jin et al. (2010) Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 54:3079-85
  61. Yang, Soo-Jin et al. (2010) Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 54:3161-9
  62. Yang, Soo-Jin et al. (2009) Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 53:2636-7
  63. Zhang, TianHua et al. (2014) Cardiolipin prevents membrane translocation and permeabilization by daptomycin. J Biol Chem 289:11584-91 PDF
  64. van Hal, S. J. et al. (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. Eur J Clin Microbiol Infect Dis 30:603-10 PDF


  1. Antachopoulos, C. et al. (2012) Serum levels of daptomycin in pediatric patients. Infection 40:367-71
  2. Bradley, John S. et al. (2014) Single-dose Pharmacokinetics of Daptomycin in Pediatric Patients 3-24 Months of Age. Pediatr Infect Dis J 33:936-9
  3. Castagnola, Elio et al. (2014) Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients. J Chemother 26:273-5
  4. Durand, Cheryl et al. (2014) Daptomycin use in pediatric patients. Am J Health Syst Pharm 71:1177-82


  1. Dubrac, Sarah et al. (2007) New insights into the WalK/WalR (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm formation in Staphylococcus aureus. J Bacteriol 189:8257-69
  2. Eisenstein, B. I. (2008) Treatment of staphylococcal infections with cyclic lipopeptides. Clin Microbiol Infect 14 Suppl 2:10-6
  3. Fukushima, Tatsuya et al. (2008) A sensor histidine kinase co-ordinates cell wall architecture with cell division in Bacillus subtilis. Mol Microbiol 69:621-32
  4. Howden, Benjamin P. et al. (2011) Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 7:e1002359
  5. Kirkpatrick, Peter et al. (2003) Daptomycin. Nat Rev Drug Discov 2:943-4
  6. Kirsch, L. E. et al. (1989) Kinetics of the aspartyl transpeptidation of daptomycin, a novel lipopeptide antibiotic. Pharm Res 6:387-93
  7. Maget-Dana, R. et al. (1988) A comparative monomolecular film study of antibiotic A21978C homologues of various lipid chain length. Biochim Biophys Acta 962:201-7 PDF
  8. Nadrah, Kristina and Strle, Franc (2011) Antibiotic combinations with daptomycin for treatment of Staphylococcus aureus infections. Chemother Res Pract 2011:619321
  9. Percy, Matthew G. and Gründling, Angelika (2014) Lipoteichoic acid synthesis and function in gram-positive bacteria. Annu Rev Microbiol 68:81-100
  10. Qiu, Jiang et al. (2011) Estimated pKa values for specific amino acid residues in daptomycin. J Pharm Sci 100:4225-33
  11. Salzberg, Letal I. and Helmann, John D. (2008) Phenotypic and transcriptomic characterization of Bacillus subtilis mutants with grossly altered membrane composition. J Bacteriol 190:7797-807
  12. Sauermann, Robert et al. (2008) Daptomycin: a review 4 years after first approval. Pharmacology 81:79-91
  13. Tótoli, Eliane Gandolpho et al. (2015) Daptomycin: Physicochemical, Analytical, and Pharmacological Properties. Ther Drug Monit 37:699-710
  14. Vilhena, C. and Bettencourt, A. (2012) Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev Med Chem 12:202-9
  15. Winkler, Malcolm E. and Hoch, James A. (2008) Essentiality, bypass, and targeting of the YycFG (VicRK) two-component regulatory system in Gram-positive bacteria. J Bacteriol 190:2645-8
  16. Yazawa, M. and Yagi, K. (1980) The amino acid sequence of the calmodulin obtained from sea anemone (Metridium senile) muscle. Biochem Biophys Res Commun 96:377-81

Structural Studies

  1. Ball, Lee-Jon et al. (2004) NMR structure determination and calcium binding effects of lipopeptide antibiotic daptomycin. Org Biomol Chem 2:1872-1878 PDF
  2. Ho, Steven W. et al. (2008) Effect of divalent cations on the structure of the antibiotic daptomycin. Eur Biophys J 37:421-433 PDF
  3. Jung, David et al. (2004) Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol 11:949-957 PDF
  4. Muraih, Jawad K. et al. (2012) Characterization of daptomycin oligomerization with perylene excimer fluorescence: stoichiometric binding of phosphatidylglycerol triggers oligomer formation. Biochim Biophys Acta 1818:673-8 PDF
  5. Qiu, Jiang and Kirsch, Lee E. (2014) Evaluation of lipopeptide (daptomycin) aggregation using fluorescence, light scattering, and nuclear magnetic resonance spectroscopy. J Pharm Sci 103:853-61 PDF
  6. Rotondi, Kenneth S. and Gierasch, Lila M. (2005) A well-defined amphipathic conformation for the calcium-free cyclic lipopeptide antibiotic, daptomycin, in aqueous solution. Biopolymers 80:374-385 PDF
  7. Scott, Walter R. P. et al. (2007) NMR structural studies of the antibiotic lipopeptide daptomycin in DHPC micelles. Biochim Biophys Acta 1768:3116-3126 PDF


  1. Bernhard, W. et al. (2000) Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 162:1524-33 PDF
  2. Frosolono, M. F. et al. (1970) Isolation, characterization, and surface chemistry of a surface-active fraction from dog lung. J Lipid Res 11:439-57 PDF
  3. Hall, S. B. et al. (1994) Separation of subfractions of the hydrophobic components of calf lung surfactant. J Lipid Res 35:1386-94 PDF
  4. He, Yong et al. (2012) Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids. Bioorg Med Chem Lett 22:6248-51 PDF
  5. King, R. J. and Clements, J. A. (1972) Surface active materials from dog lung. I. Method of isolation. Am J Physiol 223:707-14 PDF
  6. Notter, R. H. et al. (1983) Comparative adsorption of natural lung surfactant, extracted phospholipids, and artificial phospholipid mixtures to the air-water interface. Chem Phys Lipids 33:67-80 PDF
  7. Rooney, S. A. (1984) Lung surfactant. Environ Health Perspect 55:205-26 PDF
  8. Silverman, Jared A. et al. (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149-52 PDF